INTRODUCTION
The macrolide antibiotic FK 506 (tacrolimus) is a powerful new T-cell-directed immunosuppressive agent ,.~ with a similar but considerably more potent anti-lymphocytic activity compared to eyclosporin A (CSA),1 A It suppresses sekctively. the transcription of interIcukin-2 (IL-21 and other cytokine genes in CD4 + T-cell '. and 
inhibits the induction of T-cell activation
Correspondence to: Dr A. W Thomson. Pitlshurgh Transplan-'atlon Institute. UniversIt\ of Pittsburgh Medical Center. W 1544 Biomedical ScienCi.! Tllwcr. Pittsburgh. P,\ 15213 USA. T.:l: (412) marker expression (e.g. major histocompatibility complex [MHC] class II antigen and IL-2 receptor [IL-2R]) both /11 I'iiro" and following systemic immunization ill I'il'o 7 . FK 506 has been sh;\\~n to prevent and reverse human organ transplant rejection' and has recently been approved for the therapy of liver allograft rejection. The immunosuppressive ellieacy and safety of FK 506 have also been demonstrated in certain organspecific and systemic autoimmune diseases. both in animals and in preliminary clinical trials"-'. 1 . There have however. been no detailed reports of the in/luenee ofFK 506 on circulating T cells in non-transplant patients receiving the drug. \\ie have taken the opportunity of a clinical trial of the potential etlicacy and safety of FK 506 in chronic progressive mUltiple sclerosis (MS) to investigate the influence of the drug on circulating T cells in a non-transplant population that was otherwise in good health.
It is widelv believed that MS is a chronic autoimmune dise~se of the central nervous svstem (CNS) , that is mediated by T-Iymphocytes that recognize an as yet unidentified autoantigen 14. MS is associated with abnormalities in the regulation of immune reactivity, including changes in T-cell subset distribution that resemble those seen in other autoimmune diseases 14-16. Recently, significant changes in the proportion of CD4 -cells expressing the CD45 isoforms CD45RA or CD45RO/CD29. that represent different maturational stages of T cells 17 have been reported in several autoimmune l8 . 19 or immunodeficiency disorders 20 . It has been reported that. in progressi~e MS, there is a selective loss of circulating CD4 + T -cells expressing CD45RA (2H4), a marker of "suppressor-inducer" (naive) cellsl~. 21 . Therapies which may reverse this imbalance in regulatory T cell populations could prove valuable in the treatment of the disease. We have examined the intluence of FK 506 on peripheral blood CD4 + cells expressing the IL-2Ra chain (CD25) and the CD45RA isoform in 19 patients with chronic progressive MS to ascertain whether any observed changes might be related to and/or predictive of response to therapy with this important new anti-lymphocytic agent.
MATERIALS AND METHODS

SlIhjects
The 19 patients studied were pan of a randomized. drug concentration-controlled pilot study of the potential etfJcacy and safety of FK 506 in chronic progressive MS. The trial was approved by the University of Pittsburgh Medical Center (UPMC) Institutional Review Board and by the US Food and Drug Administration. Seven male and 12 female patients. age range 25-67 years (mean 43.4 ± 10.4 years) with clinically dennite MS of at least one years duration and from whom a pretreatment and sequential. 3-monthly blood samples were available were studied during outpatient visits to the UPMC. Progressive MS with accumulating disability is a clinical pattern characterized by an increase in neurological impairment and disability over time. This definition required that each patient maintained a progressive pattern with accumulating disability in the six months before entering the study. Subjects with exacerbating and remitting disease without progression were excluded. In order to be eligible tor the study. patients were at a level of disability as del1ned by the Kurtzke Expanded Disability Status Scale (EDSS)22 of grade 3.0 to 7.0 inclusive. The pretreatment Kurtzke scores ranged from 3.0-7.0 (mean 5.8 ± 1.1) and the ambulation index 23 (AI) range (see below) was 2.0-7.0 (mean 4.5±1.3) . No patients had received steroids and ACTH for at least one month, or immunosuppressive drugs for at least 3 months at the time of entry and initial blood sampling. All patients were required to be co-operative and in otherwise good general health. In particular. subjects with a history of alcoholism, hepatitic disease. renal dysfunction. cardiac disorders. pulmonary or other illnesses were excluded. Normal healthy adult controls were laboratory volunteers of both sexes with a similar age range to the MS patients.
Clinical assessment
At entry, all patients underwent an extensive physical and neurological examination and a number of hematological and blood chemical studies. Magnetic resonance imaging (MRl) was performed to confirm the diagnosis of MS. General medical examination included measurements of blood pressure, temperature, respiratory rate, weight, chest x-ray and electrocardiogram. Standard laboratory testing included the following: blood sugar, electrolytes. blood urea. serum creatinine and calcium. complete blood count, coagulation profiles. liver screen. serum amylase and urinalysis.
Neurological evaluation was conducted by neurologists trained in the application of the specific scoring systems employed during the study. Two measurement svstems were used. namelY the Kurtzke (= EDSS) -score 22 and the ambulation index (AI).n These scoring systems are commonly used in clinical trials involving MS patients. 24 The Kurtzke score involves the assessment of a variety of functional systems covering the major areas examined during clinical evaluation of the nervous system. Each of these functions is graded on a scale from 0 (normal) to maximum impairment (grade 6). Data from evaluation of individual functional systems is then incorporated into an EDSS score which ranges from grade 0 (normal neurological examination) to grade 10 (death from MS). The second clinical performance lI1dicator lIsed was the AI. This test focuses on the ability of the subject to ambulate: the grades range from 0 to 10. grade 0 being an asymptomatic. fully active individual while grade 10 applies to a totally bedridden patient. I ntervening grades are standardized to retlect progressive levels of impairment.
Patients were seen initially at entry. then at weekly intervals for one month. thereafter at monthly intervals for a period of three months. then every subsequent three months. Laboratory testing. a general medical evaluation. and neurologic functIOn were assessed at each visit. . Osaka. Japan) was started at a daily oral dose of 0.15mglkg. which represented half that given initially to organ transplant patients. This lower dose was selected to reduce the risk of side effects in a non-life-threatening condition in which there was no guarantee of therapeutic efficacy. Once therapy commenced. doses were adjusted using a dosing algorithm as described previously:!5. Dose reduction was allowed in the event of toxic side effects. The mean and median daily dose of FK 506 and early morning plasma trough levels of the drug were determined by enzyme-linked immunosorbent assay26 at 0.3.6.9 and 11 months after the start of FK 506 administration (Table I) .
lmmunophenotypic analysis orb/ood lymphocytes
Anticoagulated peripheral venous blood samples were obtained before the start of treatment (day 0) and at 7 days. 1.3.6.9 and 11 months thereafter. Mononuclear cells (MNC) were isolated from the samples by centrifugation over Histopaque (Sigma. S1. Louis. MO) and stained using standard procedures. as previously described 6 . \!louse anti-human monocloncal antibodies (mAbs) used in one or two-color !low cytometric analysis of patients' blood MNC or of those obtained from healthy adult controls included phycoerythrin (PE)-conjugated anti-CD4. PE-conjugated anti-CD8. and FITC-conjugated anti-CD15 (lL-2R. p55 a chain) and were diluted III 0 in Hanks' balanced salt solution (HBSS) with 1% bovine serum albumin (BSA) and 0.1 % NaN,. PE-conjugated mouse IgG and FITCconjugated mouse IgG were used as isotopic controls. These antibodies were purchased from Dako. Carpin- 
Statistical analyses
The rate of change in percentage of positively staining cells was determined for each patient using simple logistic regression 27 • The Wilcoxon Sign Rank test. a non-parametric equivalent to the paired "t"-test was used to compare pre-and post (12 months) FK 506 values. as well as pre-and post-treatment indices of disease activity. The Wilcoxon Rank Sum test was used to compare pre-FK 506 values and those obtained from normal volunteers.
RESULTS
Daily dose and plasma level o(FK 506
The mean and median total daily dose and 12-hr trough plasma levels of FK 506 in the 19 MS patients taking the drug continuously for 12 months are shown in Table 1 . Whilst the daily FK 506 dose rose during this period. the range became more restricted. Although the median plasma concentration of FK 506 remained unchanged throughout the study. there was \10nths after start of treatment (n; l'l) In/Illenee ofFK 506 on renal/lllletion Nephrotoxicity is one of the well-known potential side effects of FK 506 28 . As shown in Table 2 . the mean serum creatinine and blood urea nitrogen (BUN) levels rose to 1.2 and 1.3 times baseline respectively. over the 12 months of study.
Patient Disability
The mean Kurtzke EDSS score and ambulation index in the 19 MS patients over the 12-month study period are shown in As shown in Fig. I . there was a tendency to higher mean plasma FK 506 concentrations in those patients that showed improvement in Al (increase of I relative to baseline) or Kurtzke score (decrease of 0.5 relative to baseline)24 at 12 months. 
Adverse eU'eels
The ten most common adverse events recorded in the FK 506-treated patients and their prevalence of occurrence are shown in Table 4 . None of these events required specific treatment or necessitated withdrawal of patients from the study.
Expressioll o(CD25 and CD45RA Of! peripheral h/ood CD4' cells
To determine the influence of continuous systemic FK 506 administration on the percentage of activated (CD25 +) and immunoregulatory (CD45RA T) CD4 .. lymphocytes. two-color now cytometric analysis of peripheral blood MNC was performed before the start of treatment and at intervals thereafter. up to 1 year. Table 5 shows that before treatment. CD4" cells and the CD4: CD8 ratio were elevated significantly above normal. unlike CD8" cells. which were significantly decreased in the 19 patients studied. The proportion of either CD4' or CDS + cells bearing the CD25 marker was elevated above normal. as was the proportion of CD45RA + CD4 -cells. When pre-and posttreatment (12-monthl values were compared. there was no etfect of FK 506 on any of the parameters. Values obtained for CD25' and CD45RA" CD4 + cells during the 12-month study period are shown in Figure 2 . There was essentially no change in the median percentages of CD25" CD4 + cells compared with the pretreatment level during the 12 months of treatment. The proportion of CD45RA + CD4" cells also did not change signihcantly throughout the study. although the median was 25% below the pretreatment value at 12 months. 
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Progression
No change Improvement Progression No change Improvement
Change in Ambulation Index Change in Kurtzke Score 27.8 " , " ,
I
-rna\ hI..' an 0\ t'rt''llimate Ol'cau,,"' nf lilrtkuil\ In Jitkrl'nll3tlntl JI\l'Jsl'·rl'lall'd ,\ mptomawl0tl\ t"r()Ol drull-lndun'd l'flt'rt., Patients in which an increase in C045RA + C04-cells and a decrease in C025' C04 -cells was sustained for at least 2 occasions post treatment (7 subjects) were examined further. Figure 3 shows that in this sub-group of FK 506 treated patients. there was no correlation between these laboratory indices of T cell function and the clinical assessment of patient disability over the follow-up period . rived from a study of this nature Jll . Further information will be forthcoming once the full cohort of MS patients ( 105) has completed the two-year study. The 19 patIents selected for the immunological analyses represented a minor proportion of the total patient group. While no statistical information can be drawn from the clinical data. the results indicate. nonetheless. that in these patIents. at least clinical stability was c\ident throughout the course of treatment. Patients were chosen on the basis of chronic disease progressian and all had deteriorated by at least one score on the Kurtzke EDSS during the year before FK 506 administration. The mean change in Kurtzke score in the 19 FK 506-treated patients after 12 months was + 0.06 ± 0.73. Thus. the results show a trend to stabilization of the MS while on FK 506 treatment. There was also a tendency to a higher mean plasma FK 506 level in those patients that showed improvement in Kurtzke score (decrease of 0.5 relative to baseline). The side effects of the drug were mild in the 19 patients. and in no case were they deemed severe enough to warrant discontinuation of the medication.
The present study focuses on the influence of FK 506 on circulating T cells in chronic progressive MS. Previous studies have shown that activated T -cells are increased in the peripheral blood of patients with this condition J I. Moreover. T -cells expressing cell surface activation molecules. such as IL-2R and MHC class II antigens. can be identified in lesional tissue within the CNS of MS patients J2 . In the present investigation. significantly increased incidences both in circulating total C04 + cells and in the C04: C08 ratio were observed in the 19 progressive MS patients compared with healthy adult control subjects. Increases both in activated C025 + C04 + and C025 + C08 + T cells (especially) were also found compared with healthy age-and sex-matched individuals. These findings suggested impaired immune regulation. consistent with previous reports of T cell populations in this disease. In contrast with an earlier study"l. and our own previous observations on a smaller group of these patients JJ • the mean proportion of immunoregulatory C045RA + C04 + cells in peripheral blood was not decreased significantly pretreatment compared with healthy subjects. There was however. considerable inter-individual variation in this parameter. Several patients showed a decrease (> 10%) in this subset of C04 + cells that has been correlated positively with T-cell suppression and with inhibition ofT-and B-cell clones reactive with elements of the CNS 21 • Treatment with FK 506. a potent inhibitor of C04 + T-cell activation in response to stimulation via the C03/T cell receptor pathway. did not atfect significantly the proportion of either C025' or C045 RA . C04 ~ cells over a 12-month period. ~loreover. no relationship could be demonstrated between an increase in CO~5RA -C04 + cells together with a concomitant decrease in C025' C04' cells and the patients' disability status in response to FK 506. Notably. at the FK 506 doses used and at the plasma levels achieved (which are anti-lymphocytic 111 l'ill"O.l.l. 5 .b and similar to or lower than those reported previously in patients with uveitis.14. or psoriasis"l there was no significant overall change in the clinical status of the MS patients.
While this study has examined the int1uence of FK 506 on non-specific indices of peripheral hlood C04 + cell activation and function. the possibility that this new anti-T cell agent might exert elfects on the function of specific. disease-associated T cells hoth within the hlood and more significantly. within the eNS. cannot be excluded. Indeed. local inhibition of intlammatorv events within the skin have recentlv been repofted i;l FK 506-tre~lted psoriasis patients.· 1115 . 1 (, Although FK 506 has not been detected in the cerebrospinal fluid of several organ transplant patients with very high plasma drug [e\'els exhibiting toxic manifestations of FK 506 (R. Venkataramanan. Dept. of Pharmacy. University of Pittsburgh: personal communication) studies on T-cell populations within lesional tissue of FK 506-treated patients with preeXlst1l1g neurological disease would be very informative.
